Pharmaceutical Excipients: Types, Functions and Their Role in Drug Formulation

Pharmaceutical excipients are the non-API components of a finished drug product, included to give the dosage form its physical structure, control how and when the API is released, and make the product manufacturable, stable and acceptable to patients.

Although regulatory documentation often refers to excipients as “inactive ingredients,” that label describes their lack of direct pharmacological action against the condition being treated, not their impact on the product. The specific excipients chosen, their grades, and their proportions in a formulation directly affect tablet hardness, disintegration time, dissolution rate, stability during storage, and ultimately how much and how quickly the API becomes available in the body — which is why excipient choice is documented and justified as part of every regulatory drug submission.

Fillers, also called diluents, add bulk to a formulation so that a tablet or capsule containing a small amount of a potent API still reaches a practical, handleable size, while also contributing to the compressibility and flow properties of the powder blend.

Microcrystalline cellulose is one of the most widely used fillers, valued for its excellent compressibility and binding ability, which is why it is also sometimes classed as a binder. Lactose monohydrate is another standard filler, prized for its flow and compression properties, though formulators must consider it for patients with lactose intolerance or in Maillard-reaction-sensitive formulations. Mannitol, a sugar alcohol, is often chosen for chewable tablets and orally disintegrating formulations because of its pleasant taste and low hygroscopicity compared with other sugar-based fillers.

Binders are excipients that hold powder particles together during wet or dry granulation and subsequent compression, giving the tablet enough mechanical strength to survive packaging, shipping and handling without crumbling.

Povidone, commonly supplied as PVP K30, is a widely used binder added either as a dry powder or dissolved in a granulating solvent, prized for strong binding at relatively low usage levels. HPMC (hydroxypropyl methylcellulose) also serves as a binder in many formulations, in addition to its separate role as a film-coating polymer, making it one of the more versatile excipients in a formulator's toolkit. The right binder concentration is a balancing act: too little and the tablet is friable; too much and it may disintegrate and dissolve too slowly.

Disintegrants are included in a tablet formulation specifically to make the compressed tablet break apart quickly once it contacts gastrointestinal fluid, exposing the API's surface area so it can dissolve and be absorbed rather than passing through the body as a slow-dissolving mass.

Croscarmellose sodium is one of the most widely used “superdisintegrants,” valued for achieving rapid tablet breakup at a lower usage level than older disintegrants like plain starch, working by rapidly absorbing water and swelling to pull the tablet matrix apart. Disintegrant choice and level are especially critical for immediate-release formulations, where rapid onset of dissolution is a key performance target, and are deliberately minimised or excluded in sustained-release formulations designed to release the API slowly over time.

Lubricants reduce friction between the powder blend and the tableting equipment, preventing the tablet from sticking to the punches and dies during compression, while glidants improve powder flow so the blend feeds consistently into the tablet press.

Magnesium stearate is the most widely used tablet lubricant, effective at very low concentrations, typically under one percent of the formulation. Because it is hydrophobic, however, too much magnesium stearate can slow water penetration into the tablet and delay disintegration and dissolution, which is why formulators carefully control both the lubricant level and the mixing time to avoid over-lubrication.

Coating agents are applied as a thin film over a finished tablet or bead to protect the API from moisture and light, mask unpleasant taste, make the tablet easier to swallow, or control where and how fast the drug is released, while solubility enhancers help poorly water-soluble APIs dissolve more effectively.

HPMC is one of the most common film-coating polymers, used both for simple cosmetic and protective coatings and, at different substitution grades, for controlled-release coatings that slow drug release over an extended period. Polyethylene glycol (PEG) serves multiple roles across formulation: as a plasticiser in film coatings, as a solubility-enhancing excipient in certain oral and topical formulations, and as a base for suppositories and some semi-solid dosage forms, with the specific molecular weight grade (commonly PEG 400, PEG 4000 or PEG 6000) chosen to match the required viscosity and melting behaviour.

Formulators should select excipient grade based on the specific functional requirement of the formulation — particle size and compressibility for fillers, viscosity grade for binders and coating polymers, molecular weight for PEG — rather than treating excipients within the same chemical family as interchangeable.

Because grade differences can meaningfully change how an excipient performs, formulators typically specify not just the excipient name but the exact grade (for example, a specific HPMC viscosity grade or PEG molecular weight) in the formulation record, and any change requires requalification through compressibility, disintegration, dissolution or stability testing as appropriate. Sourcing from qualified manufacturers with consistent, batch-to-batch quality is just as important as the initial grade selection, since variability in particle size distribution or viscosity between batches of nominally the same excipient grade can still affect manufacturability and product performance.

Buyers should source pharmaceutical excipients by confirming the exact grade and compendial specification needed, verifying documentation, and sourcing from manufacturers with demonstrated GMP and batch consistency. Six practical steps follow.

1. 1

   Confirm the exact excipient and grade needed

   Specify not just the excipient (e.g. HPMC) but the exact grade (viscosity, substitution type) your formulation requires.

2. 2

   Confirm compendial compliance

   Verify the material meets the relevant USP-NF, Ph. Eur. or IP monograph your regulatory filing references.

3. 3

   Request the certificate of analysis and safety data sheet

   Check every batch against your approved specification before release to production.

4. 4

   Confirm GMP sourcing and batch traceability

   Work with suppliers who can document the manufacturing facility and provide lot traceability for audit and regulatory purposes.

5. 5

   Request samples before committing to bulk volume

   Test any new excipient source or grade against your formulation at lab scale before placing a full production order.

6. 6

   Never change grade or source without requalification

   Treat any excipient grade or supplier change as a formulation change requiring the appropriate testing and documentation.

Pharmaceutical excipients evolved from simple, often improvised fillers and binders used in early compressed tablets in the late nineteenth and early twentieth centuries into a rigorously standardised, compendially regulated category of ingredients as the pharmaceutical industry professionalised through the twentieth century.

Early tablets relied on basic materials like starch and sugar for bulk and binding, with little formal characterisation of how these materials affected drug release. As understanding of dissolution, bioavailability and bioequivalence advanced through the mid-twentieth century, particularly after several well-documented cases where formulation and excipient changes caused clinically significant shifts in drug absorption, regulators and compendial bodies developed formal monographs and specifications for excipients, and functional categories such as superdisintegrants (like croscarmellose sodium) and high-performance binders (like povidone) were developed specifically to improve manufacturability and drug performance. Today, excipient selection and qualification is a core, documented part of pharmaceutical development, supported by compendial standards, regulatory databases like the FDA's Inactive Ingredient Database, and increasingly sophisticated formulation science.